An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Trial Profile

An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Fludarabine; Prednisone; Vincristine
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms GAUDI
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2014 Final results from maintenance phase presented at 56th American Society of Hematology Annual Meeting, according to a Genentech media release.
    • 05 Dec 2014 Status changed from active, no longer recruiting to completed, according to Genentech media release.
    • 03 Nov 2014 Status changed from active, no longer recruiting to recruiting as reported by as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top